Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
cortisone	O
Attending:	O
___.	O
Chief	O
Complaint:	O
post	O
TACE	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
TACE	O
___	O
History	O
of	O
Present	O
Illness:	O
Patient	O
is	O
a	O
___	O
year	O
old	O
man	O
with	O
segment	O
6	O
lesion	O
4.4cm	O
meeting	O
OPTN	O
criteria	O
for	O
___	O
who	O
is	O
s/p	O
TACE,	O
admitted	O
for	O
observation.	O
Prior	O
to	O
recent	O
months,	O
patient	O
had	O
no	O
known	O
history	O
of	O
liver	O
disease,	O
and	O
initially	O
presented	O
to	O
his	O
PCP	O
with	O
___	O
pain	O
and	O
was	O
sent	O
for	O
an	O
ultrasound	O
which	O
showed	O
an	O
echogenic	O
liver	O
and	O
indeterminate	O
liver	O
lesion.	O
An	O
MRI	O
on	O
___	O
showed	O
evidence	O
of	O
cirrhosis	O
including	O
portal	O
vein	O
hypertension	O
and	O
splenomegaly.	O
A	O
4.4cm	O
lesion	O
in	O
segment	O
6	O
was	O
concerning	O
for	O
___	O
as	O
was	O
a	O
nonspecific	O
sub-cm	O
focus	O
in	O
segment	O
6.	O
A	O
CT-duided	O
liver	O
biopsy	O
at	O
OSH	O
was	O
not	O
performed	O
given	O
suboptimal	O
visualization	O
of	O
the	O
lesion.	O
However	O
evaluation	O
of	O
the	O
lesion	O
by	O
radiology	O
here	O
demonstrated	O
it	O
to	O
meet	O
OPTN	O
criteria	O
for	O
HCC;	O
therfore	O
it	O
did	O
not	O
require	O
a	O
biopsy.	O
Today,	O
he	O
underwent	O
TACE	O
via	O
left	O
radial	O
artery	O
access	O
with	O
CT-guided	O
chemoembolization	O
delivered	O
to	O
the	O
segment	O
6	O
lesion,	O
followed	O
by	O
gel	O
foam.	O
He	O
had	O
headache	O
post	O
procedure,	O
given	O
oxycodone.	O
On	O
arrival	O
to	O
floor,	O
denies	O
any	O
sxs.	O
Past	O
Medical	O
History:	O
Hepatocellular	O
Carcinoma	O
CKD	O
stage	O
III	O
DM	O
diabetic	O
retinopathy	O
HTN	O
hyperlipidemia	O
gastric	O
ulcer	O
(___)	O
nephrolithiasis	O
Social	O
History:	O
___	O
Family	O
History:	O
Family	O
Liver	O
History:	O
maternal	O
uncles	O
X3	O
with	O
liver	O
disease	O
of	O
unknown	O
origin	O
Physical	O
Exam:	O
ADMISSION	O
Gen:	O
NAD,	O
lying	O
in	O
bed	O
Eyes:	O
EOMI,	O
sclerae	O
anicteric	O
ENT:	O
MMM,	O
OP	O
clear	O
Cardiovasc:	O
RRR,	O
no	O
MRG,	O
full	O
pulses,	O
no	O
edema	O
Resp:	O
normal	O
effort,	O
no	O
accessory	O
muscle	O
use,	O
lungs	O
CTA	O
___.	O
GI:	O
soft,	O
NT,	O
ND,	O
BS+	O
MSK:	O
No	O
significant	O
kyphosis.	O
No	O
palpable	O
synovitis.	O
Skin:	O
No	O
visible	O
rash.	O
No	O
jaundice.	O
Neuro:	O
AAOx3.	B-Delirium
No	O
facial	O
droop.	O
Psych:	O
Full	O
range	O
of	O
affect	O
DISCHARGE	O
VS:	O
98.7	O
PO	O
94	O
/	O
57	O
80	O
18	O
95	O
Ra	O
___:	O
___	O
Gen:	O
sitting	O
up	O
in	O
bed,	O
comfortable	O
appearing	O
Eyes	O
-	O
EOMI	O
ENT	O
-	O
OP	O
clear,	O
MMM	O
Heart	O
-	O
RRR	O
no	O
mrg	O
Lungs	O
-	O
CTA	O
bilaterally	O
Abd	O
-	O
soft	O
nontender,	O
normoactive	O
bowel	O
sounds	O
Ext	O
-	O
no	O
edema	O
Skin	O
-	O
no	O
rashes	O
Vasc	O
-	O
2+	O
DP/radial	O
pulses;	O
radial	O
site	O
with	O
small	O
superficial	O
ecchymosis;	O
no	O
pulsatile	O
mass;	O
Neuro	O
-	O
AOx3;	B-Delirium
no	O
cogwheel	O
rigidity,	O
___	O
strength	O
in	O
lower	O
extremities;	O
gait	O
observed,	O
much	O
more	O
steady	O
than	O
day	O
prior	O
with	O
RN	O
assistance	O
Psych	O
-	O
appropriate	O
Pertinent	O
Results:	O
ADMISSION	O
___	O
12:30AM	O
BLOOD	O
WBC-10.5*	O
RBC-3.43*#	O
Hgb-11.0*#	O
Hct-31.9*#	O
MCV-93	O
MCH-32.1*	O
MCHC-34.5	O
RDW-13.6	O
RDWSD-45.7	O
Plt	O
Ct-75*	O
___	O
07:15AM	O
BLOOD	O
Glucose-294*	O
UreaN-27*	O
Creat-1.3*	O
Na-139	O
K-3.9	O
Cl-102	O
HCO3-23	O
AnGap-18	O
___	O
10:50AM	O
BLOOD	O
ALT-45*	O
AST-46*	O
AlkPhos-92	O
TotBili-1.0	O
DISCHARGE	O
___	O
07:00AM	O
BLOOD	O
WBC-9.3	O
RBC-3.12*	O
Hgb-10.0*	O
Hct-29.1*	O
MCV-93	O
MCH-32.1*	O
MCHC-34.4	O
RDW-13.5	O
RDWSD-45.5	O
Plt	O
Ct-58*	O
___	O
07:00AM	O
BLOOD	O
Glucose-97	O
UreaN-23*	O
Creat-1.2	O
Na-137	O
K-3.8	O
Cl-102	O
HCO3-26	O
AnGap-13	O
___	O
07:00AM	O
BLOOD	O
ALT-118*	O
AST-104*	O
AlkPhos-68	O
TotBili-1.3	O
___	O
-	O
CHEMO	O
EMBOLIZATION	O
1.	O
Variant	O
hepatic	O
arterial	O
anatomy	O
with	O
a	O
trifurcation	O
at	O
the	O
level	O
of	O
the	O
celiac	O
;	O
the	O
right	O
hepatic	O
artery	O
arises	O
directly	O
from	O
the	O
proximal	O
celiac	O
artery.	O
2.	O
Pre-embolization	O
right	O
hepatic	O
arteriogram	O
showing	O
tumor	O
blush	O
in	O
segment	O
6.	O
3.	O
Cone-beam	O
CT	O
showing	O
small	O
tumor	O
feeding	O
vessels	O
arising	O
from	O
the	O
posterior	O
branch	O
of	O
the	O
right	O
hepatic	O
artery.	O
4.	O
Post-embolization	O
showing	O
mi	O
staining	O
of	O
tumor	O
in	O
segment	O
6.	O
5.	O
Post	O
embolization	O
cone	O
beam	O
CT	O
showing	O
staining	O
of	O
the	O
majority	O
of	O
the	O
posterior	O
right	O
hepatic	O
lobe,	O
including	O
the	O
segment	O
6	O
lesion.	O
Brief	O
Hospital	O
Course:	O
This	O
is	O
a	O
___	O
year	O
old	O
male	O
with	O
past	O
medical	O
history	O
of	O
CKD	O
stage	O
3,	O
diabetes	O
type	O
2	O
complicated	O
by	O
retinopathy,	O
hepatocellular	O
carcinoma,	O
admitted	O
following	O
elective	O
trans-arterial	O
chemoembolization,	O
course	O
complicated	O
by	O
gait	O
instability	O
and	O
hyperglycemia,	O
resolved	O
and	O
able	O
to	O
be	O
discharged	O
home	O
#	O
Hepatocellular	O
Carcinoma	O
status	O
post	O
TACE	O
-	O
On	O
___,	O
patient	O
underwent	O
chemoembolization	O
of	O
segment	O
VI	O
lesion.	O
His	O
discharge	O
LFTs	O
were	O
ALT	O
118,	O
AST	O
104,	O
AP	O
68,	O
Tbili	O
1.3.	O
Could	O
consider	O
recheck	O
at	O
follow-up	O
to	O
ensure	O
normalization	O
to	O
his	O
baseline	O
#	O
Type	O
2	O
diabetes	O
complicated	O
by	O
hyperglycemia	O
-	O
Patient	O
course	O
notable	O
for	O
post-procedure	O
hyperglycemia.	O
Patient	O
also	O
reported	O
chronically	O
elevated	O
fingersticks	O
at	O
home,	O
which	O
his	O
wife	O
attributed	O
to	O
poor	O
dietary	O
compliance.	O
Given	O
___,	O
patient	O
remained	O
in	O
the	O
hospital	O
for	O
1	O
extra	O
day	O
for	O
glucose	O
control	O
optimization.	O
No	O
modifications	O
were	O
necessary	O
to	O
home	O
regimen--just	O
dietary.	O
Continued	O
home	O
insulin	O
regimen	O
and	O
patient	O
and	O
wife	O
received	O
counseling	O
from	O
nutritionist	O
re:	O
diabetic	O
diet.	O
___	O
<	O
180	O
prior	O
to	O
discharge.	O
Continued	O
home	O
___	O
(received	O
glargine	O
while	O
inpatient),	O
standing	O
humalog	O
and	O
glipizide.	O
Held	O
metformin	O
x	O
72	O
hours	O
post	O
embolization.	O
#	O
Gait	O
instability	O
-	O
Patient	O
was	O
noted	O
to	O
be	O
quite	O
deconditioned	O
with	O
gait	O
instability.	O
Wife	O
reported	O
recent	O
falls	B-Falls
at	O
home.	O
Patient	O
was	O
seen	O
by	O
___	O
and	O
after	O
2	O
visits	O
he	O
was	O
cleared	O
for	O
home	O
with	O
services	O
and	O
a	O
rolling	O
walker.	B-Mobile_with_aid
Patient	O
provided	O
with	O
rolling	O
walker	B-Mobile_with_aid
prior	O
to	O
discharge.	O
Discharged	O
with	O
home	O
___.	O
#	O
Thrombocytopenia	O
-	O
During	O
this	O
admisison,	O
patient	O
noted	O
to	O
have	O
thrombocytopenia.	O
On	O
review	O
of	O
prior	O
records	O
from	O
___	O
and	O
___,	O
it	O
appears	O
this	O
has	O
been	O
noted	O
previously.	O
Suspect	O
this	O
is	O
secondary	O
to	O
his	O
chronic	O
liver	O
disease.	O
Plt	O
at	O
discharge	O
were	O
58k.	O
#	O
Hypertension	O
#	O
Hyperlipidemia	O
Continued	O
Lisinopril,	O
statin,	O
HCtz	O
#	O
Depression	O
-	O
Continued	O
Venlafaxine	O
Transitional	O
Issues	O
-	O
Reported	O
poorly	O
controlled	O
fingersticks	O
at	O
home	O
as	O
high	O
as	O
300;	O
here	O
immediately	O
post-procedure	O
he	O
was	O
hyperglycemic,	O
but	O
improved	O
to	O
<	O
180	O
after	O
re-initiation	O
of	O
his	O
home	O
regimen;	O
was	O
seen	O
by	O
nutritional	O
counselor	O
given	O
concern	O
for	O
dietary	O
compliance	O
at	O
home--would	O
consider	O
further	O
dietary	O
counseling	O
as	O
an	O
outpatient;	O
-	O
Recommended	O
to	O
hold	O
metformin	O
x	O
72	O
hours	O
after	O
his	O
TACE	O
-	O
Thrombocytopenia	O
noted	O
during	O
admission,	O
thought	O
to	O
relate	O
to	O
his	O
chronic	O
liver	O
disease;	O
would	O
consider	O
recheck	O
at	O
follow-up	O
(discharge	O
platelets	O
=	O
58)	O
-	O
Discharged	O
with	O
rolling	O
walker	O
and	O
home	O
physical	O
therapy	O
-	O
Scheduled	O
for	O
___	O
and	O
___	O
follow-up	O
-	O
LFTs	O
at	O
discharge	O
were	O
ALT	O
118,	O
AST	O
104,	O
AP	O
68,	O
Tbili	O
1.3;	O
could	O
consider	O
recheck	O
at	O
follow-up	O
to	O
ensure	O
normalization	O
to	O
his	O
baseline	O
>30	O
minutes	O
spent	O
on	O
this	O
discharge	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Atorvastatin	O
40	O
mg	O
PO	O
QPM	O
2.	O
GlipiZIDE	O
10	O
mg	O
PO	O
DAILY	O
3.	O
HumaLOG	O
(insulin	O
lispro)	O
30	O
units	O
subcutaneous	O
BID	O
4.	O
Glargine	O
70	O
Units	O
Bedtime	O
5.	O
Lisinopril	O
40	O
mg	O
PO	O
DAILY	O
6.	O
Hydrochlorothiazide	O
25	O
mg	O
PO	O
DAILY	O
7.	O
MetFORMIN	O
(Glucophage)	O
1000	O
mg	O
PO	O
BID	O
8.	O
Venlafaxine	O
37.5	O
mg	O
PO	O
BID	O
9.	O
Cyanocobalamin	O
1000	O
mcg	O
PO	O
DAILY	O
Discharge	O
Medications:	O
1.	O
Atorvastatin	O
40	O
mg	O
PO	O
QPM	O
2.	O
Cyanocobalamin	O
1000	O
mcg	O
PO	O
DAILY	O
3.	O
GlipiZIDE	O
10	O
mg	O
PO	O
DAILY	O
4.	O
HumaLOG	O
(insulin	O
lispro)	O
30	O
units	O
subcutaneous	O
BID	O
5.	O
Hydrochlorothiazide	O
25	O
mg	O
PO	O
DAILY	O
6.	O
Toujeo	O
70	O
Units	O
Bedtime	O
7.	O
Lisinopril	O
40	O
mg	O
PO	O
DAILY	O
8.	O
Venlafaxine	O
37.5	O
mg	O
PO	O
BID	O
9.	O
HELD-	O
MetFORMIN	O
(Glucophage)	O
1000	O
mg	O
PO	O
BID	O
This	O
medication	O
was	O
held.	O
Do	O
not	O
restart	O
MetFORMIN	O
(Glucophage)	O
until	O
evening	O
of	O
___	O
10.___	O
Rolling	O
Walker	O
Prognosis:	O
Good	O
Length	O
of	O
Need:	O
13	O
months	O
Diagnosis:	O
R26.9	O
gait	O
instability	O
Discharge	O
Disposition:	O
Home	O
With	O
Service	O
Facility:	O
___	O
Discharge	O
Diagnosis:	O
#	O
Hepatocellular	O
Carcinoma	O
status	O
post	O
TACE	O
#	O
Type	O
2	O
diabetes	O
complicated	O
by	O
hyperglycemia	O
#	O
Gait	O
instability	O
#	O
Thrombocytopenia	O
#	O
Hypertension	O
#	O
Hyperlipidemia	O
#	O
Depression	O
Discharge	O
Condition:	O
Mental	B-Delirium
Status:	B-Delirium
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Mobile_with_aid
-	O
requires	O
assistance	B-Mobile_with_assistance
or	O
aid	B-Mobile_with_aid
(walker	O
or	O
cane).	O
Discharge	O
Instructions:	O
Mr.	O
___:	O
It	O
was	O
a	O
pleasure	O
caring	O
for	O
you	O
at	O
___.	O
You	O
were	O
admitted	O
after	O
a	O
TACE	O
(trans-arterial	O
chemoembolization).	O
While	O
you	O
were	O
here	O
you	O
were	O
seen	O
by	O
a	O
physical	O
therapist	O
who	O
recommended	O
a	O
rolling	O
walker	B-Mobile_with_aid
and	O
home	O
physical	O
therapy.	O
You	O
are	O
now	O
ready	O
for	O
discharge.	O
Please	O
do	O
not	O
take	O
your	O
metformin	O
until	O
72	O
hours	O
after	O
your	O
TACE	O
procedure.	O
It	O
will	O
be	O
important	O
for	O
you	O
to	O
follow-up	O
with	O
your	O
primary	O
care	O
doctor	O
___	O
help	O
manage	O
your	O
diabetes),	O
as	O
well	O
as	O
the	O
radiologists	O
and	O
liver	O
doctors	O
___	O
your	O
hepatocellular	O
carcinoma)	O
Followup	O
Instructions:	O
___	O

